继续讨论：物质诱导还是物质相关原发性精神病？——对I.A.Fedotov等人的回应

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

本封致编辑的信将继续《物质诱发精神病和精神分裂症：相互作用点》（Fedotov I.A., Quattrone D., Shustov D.I. Substance-induced psychosis and schizophrenia: the interaction point. I.P. Pavlov Russian Medical Biological Herald. 2020;28(4):593-604. doi:10.23888/PAVLOVJ2020284593-604)一文的作者发起的讨论，探讨继发性精神病和精神分裂症之间的异同。

作者简介

Michelle Cherro

American University of Beirut

编辑信件的主要联系方式.
Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-4526-2595

MD, Post-Graduate Resident, Department of Psychiatry, Faculty of Medicine

黎巴嫩, Beirut, Lebanon

Chonnakarn Jatchavala

Prince of Songkla University

Email: mc119@aub.edu.lb
ORCID iD: 0000-0001-9765-2184

MD, M.Sc., Department of Psychiatry, Faculty of Medicine

泰国, Songkla, Hat Yai, Thailand

DJibril I.M. Handuleh

Saint Paul's Hospital Millennium Medical College

Email: mc119@aub.edu.lb
ORCID iD: 0000-0003-2662-1078

MD, Resident, Department of Psychiatry

埃塞俄比亚, Addis Ababa, Ethiopia

Ramdas Ransing

BKL Walawalkar Rural Medical College

Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-5040-5570

MD, Assistant Professor, Department of Psychiatry

印度, Maharashtra, India

Sheikh Shoib

Jawahar Lal Nehru Memorial Hospital

Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-3739-706X

MD, Psychiatrist, Department of Psychiatry

印度, Rainawari, Kashmir, India

Dorottya Őri

Heim Pál National Pediatric Institute

Email: mc119@aub.edu.lb
ORCID iD: 0000-0003-0878-165X

MD, Child and adolescent psychiatrist, Department of Mental Health

匈牙利, Budapest, Hungary

Margaret Ojeahere

Jos University Teaching Hospital

Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-0593-2400

MD, Psychiatrists, Department of Psychiatry

尼日利亚, Jos, Plateau State, Nigeria

Joan Soler-Vidal

FIDMAG Research Foundation

Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-9809-8477

MD, Researcher

西班牙, Barcelona, Spain

Victor Pereira-Sanchez

NYU Grossman School of Medicine

Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-2576-1549

MD, Clinical Instructor

美国, New York, USA

参考

  1. Beckmann D, Lowman KL, Nargiso J, et al. Substance-induced Psychosis in Youth. Child and Adolescent Psychiatric Clinics of North America. 2020; 29(1):131-43. doi: 10.1016/j.chc.2019.08.006
  2. Fiorentini A, Volonteri LS, Dragogna F, et al. Substance-induced psychoses: a critical review of the literature. Current Drug Abuse Reviews. 2011;4(4): 228-40. doi: 10.2174/1874473711104040228
  3. Smith MJ, Thirthalli J, Abdallah AB, et al. Prevalence of Psychotic Symptoms in Substance Users: A Comparison across Substances. Comprehensive Psychiatry. 2009;50(3):245-50. doi: 10.1016/j.comp psych.2008.07.009
  4. Biedermann F, Fleischhacker WW. Psychotic disorders in DSM-5 and ICD-11. CNS Spectrums. 2016; 21(4):349-54. doi: 10.1017/S1092852916000316
  5. Kraan T, Velthorst E, Koenders L, et al. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and metaanalysis. Psychological Medicine. 2016;46(4):673-81. doi: 10.1017/S00332 91715002329
  6. Fedotov IA, Quattrone D, Shustov DI. Substance-induced psychosis and schizophrenia: the interaction point. I.P. Pavlov Russian Medical Biological Herald. 2020;28(4):593-604. (In Russ). doi:10.23888/ PAVLOVJ2020284593-604
  7. Ham S, Kim TK, Chung S, et al. Drug Abuse and Psychosis: New Insights into Drug-induced Psychosis. Experimental Neurobiology. 2017;26(1):11-24. doi: 10.5607/en.2017.26.1.11
  8. Dragogna F, Mauri MC, Marotta G, et al. Brain Metabolism in Substance-Induced Psychosis and Schizophrenia: A Preliminary PET Study. Neuropsychobiology. 2014;70(4):195-202. doi:10.1159/ 000366485
  9. Fischer M. Psychoses in the offspring of schizophrenic monozygotic twins and their normal cotwins. The British Journal of Psychiatry. 1971;118 (542):43-52. doi: 10.1192/bjp.118.542.43
  10. Ziedonis DM, Fisher W. Assessment and Treatment of Comorbid Substance Abuse in Individuals with Schizophrenia. Psychiatric Annals. 1994;24(9):477-83. doi: 10.3928/0048-5713-19940901-10
  11. Jatchavala C, Vittayanont A. Post-Traumatic Stress Disorder Symptoms among Patients with Substance-Related Disorders in the Restive A. Songklanagarind Medical Journal. 2017;35(2):121-32. doi: 10.31584/smj.2017.35.2.694
  12. Fowles DC. Schizophrenia: diathesis-stress revisited. Annual Review of Psychology. 1992;43:303-36. doi: 10.1146/annurev.ps.43.020192.001511
  13. Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophrenia Bulletin. 1990;16(1):31-56. doi: 10.1093/schbul/16.1.31
  14. Green AI, Zimmet SV, Strous RD, et al. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard Review Psychiatry. 1999; 6(6):287-96. doi: 10.3109/10673229909017206
  15. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: A review of etiological theories. Addictive Behaviors. 1998;23(6):717-34.
  16. Khokhar JY, Dwiel LL, Henricks AM, et al. The link between schizophrenia and substance use disorder: a unifying hypothesis. Schizophrenia Research. 2018;194:78-85. doi: 10.1016/j.schres.2017.04.016
  17. Guloksuz S, van Os J. The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. Psychological Medicine. 2018; 48(2):229-44. doi: 10.1017/S0033291717001775
  18. Kendler KS, Ohlsson H, Sundquist J, et al. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample. American Journal of Psychiatry. 2019;176(9):711-9. doi: 10.1176/appi. ajp.2019.18101217
  19. Starzer MSK, Nordentoft M, Hjorthøj C. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. American Journal of Psychiatry. 2018;175(4):343-50. doi: 10.1176/appi.ajp.2017.17020223
  20. Deng X, Huang Z, Li X, et al. Long-term follow-up of patients treated for psychotic symptoms that persist after stopping illicit drug use. Shanghai Archives of Psychiatry. 2012;24(5):271-8. doi: 10.3969/j.issn. 1002-0829.2012.05.004
  21. Solanki RK, Singh P, Midha A, et al. Schizophrenia: Impact on quality of life. Indian Journal of Psychiatry. 2008;50(3):181-6. doi: 10.4103/0019-5545.43632
  22. Auquier P, Lançon C, Rouillon F, et al. Mortality in schizophrenia. Pharmacoepidemiology and Drug Safety. 2006;15(12):873-9. doi: 10.1002/pds.1325
  23. McEvoy JP. The importance of early treatment of schizophrenia. Behavioral Healthcare. 2007;27(4):40-3

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © ООО "Эко-Вектор", 2021


 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).